Skip to main content


Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Fig. 5

SF-36 domain score changes from baseline for CRP > ULN population: weeks 16 (a) and 24 (b). *Statistically significant difference. BP bodily pain, CI confidence interval, CRP C-reactive protein, GH general health, MH mental health, PF physical function, RE role–emotional, RP role–physical, SE standard error, SF social function, SF-36 Short Form-36, VT vitality

Back to article page